Episode 25 - Reduced comorbidity in patients with psoriasis treated with GLP-1RA

In this episode of BJD Talks, Sam and Meera discuss the article ‘Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study’ by Olbrich et al. The full article can be accessed at https://doi.org/10.1093/bjd/ljaf346

*This podcast was generated by an AI tool created by 67Bricks for the British Association of Dermatologists* 

Transcript

SPEAKER_01 0:00

Welcome to BJD Talks, the official podcast of the BJD. I'm Sam.

SPEAKER_00 0:04

And I'm Mira. In this episode, we will be discussing the article by Henning Olbrich et al. Glucagon-like peptide 1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis, published in September 2025 and included in the January 2026 issue.

SPEAKER_01 0:25

Psoriasis is often in the spotlight due to its visible symptoms and its impact on quality of life. But the article we're discussing goes deeper. It highlights serious, sometimes overlooked comorbidities like cardiovascular diseases, metabolic syndromes, and psychiatric challenges such as depression.

SPEAKER_00 0:44

Indeed, these are key concerns for dermatologists managing psoriasis patients. This study explores whether GLP1 receptor agonists, originally used for type 2 diabetes and obesity, could offer broader benefits. And the results are compelling.

SPEAKER_01 0:59

Let's break it down. The researchers conducted a retrospective cohort study using the TriNetX database, which spans data from over 110 million US patients. They focused on psoriasis patients with obesity or type 2 diabetes, comparing those on GLP1 receptor agonists like semaglutide with those on alternative systemic treatments.

SPEAKER_00 1:22

They applied one-to-one propensity score matching to balance factors like age, sex, cardiovascular risks, and psychiatric history. After matching, each group included 3,048 patients, followed over two years. They also used sensitivity analyses to strengthen the findings.

SPEAKER_01 1:41

Here's the remarkable bit. They also saw a 44% lower risk of major adverse cardiac events, such as heart failure, stroke, or myocardial infarction.

SPEAKER_00 1:59

It doesn't stop there. Psychiatric risks also decreased significantly, with a 65% reduction in alcohol abuse and a 49% drop in substance abuse. While the reduction in suicidal ideation didn't reach statistical significance, the broader psychiatric benefits are striking.

SPEAKER_01 2:18

The mechanisms offer some clues. GLP1 receptor agonists mimic GLP1, a hormone that influences satiety, reduces inflammation, and modulates the brain's dopamine system, potentially explaining the reduced substance and alcohol dependency.

SPEAKER_00 2:34

And they may also impact psoriasis through inflammation reduction. Psoriasis is inflammatory by nature, and GLP1 receptor agonists appear to modulate immune responses, particularly via interleukins, aligning with studies showing reduced inflammatory markers.

SPEAKER_01 2:50

There are limitations though. Retrospective studies can't prove causation, and the coding system might underreport some conditions like metabolic syndromes. Prospective studies would help verify these findings.

SPEAKER_00 3:03

True, but this study gives a lot to think about. The greater risk reductions in psoriasis patients compared to those without psoriasis suggests some unique benefits. Dermatologists now have more evidence to consider GLP1 receptor agonists for comprehensive care.

SPEAKER_01 3:19

To summarize, these drugs significantly lower mortality, major cardiac risks, and psychiatric complications in psoriasis patients, making them strong candidates for wider use. The safety profile here was also reassuring, with no rise in adverse effects.

SPEAKER_00 3:34

Absolutely. This could transform systemic psoriasis management and foster collaborations between dermatologists, endocrinologists, and cardiologists. It's an exciting area of research. Bye for now.